Concurrently with these guidelines, NASS developed Appropriate Use Criteria to determine appropriate (or reasonable) ...

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

A recent rulemaking regarding patient care decision support tools is an important step forward in ensuring safety and equity ...